PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,690,918 | PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates In force · High confidence UsedRemaining | ADC Therapeutics S.A. | In force | High confidence | ||
| US 10,722,594 | PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates In force · High confidence | ADC Therapeutics S.A. | In force | High confidence | ||
| US 9,919,056 | PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates Lapsed Mar 20, 2026 on the fee record High confidence | ADC Therapeutics S.A. | Lapsed Mar 20, 2026 on the fee record | High confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by ADC Therapeutics S.A..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.